Richard Paicius, MD
Pain Medicine · Newport Beach, CANPI 1326011388
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Abbott at 36.9% of the total. Reporting peaked in 2019 at $48,205 and has fallen 93.3% since, to $3,250 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,165 payments — averaging $166.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$72K
- Vertiflex, Inc.$37K
- Vertos Medical, Inc.$25K
- Biotronik NRO, Inc.$16K
- Spinal Simplicity, LLC$15K
- Boston Scientific$14K
- plus $15K from 54 others
Across 53 payments — averaging $2007.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mesoblast, Inc.$60K
- Vertos Medical, Inc.$20K
- Abbott$18K
- Nevro Corp.$8K
- Stryker$1K
- Vertiflex, Inc.$200
- plus $100 from 1 others
What the payments were for
- Consulting fees$49,30325%
- Speaking & faculty fees$81,55842%
- Travel & lodging$20,30510%
- Food & beverage$35,47218%
- Education$6,7693%
- Gifts$5920%
- Entertainment$2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion ISS$36,036
- Neuromodulation Dspsbls and Accs$26,757
- mild Device Kit$24,395
- PROCLAIM$21,398
- Prospera$14,547
- HA MINUTEMAN G3-R$14,402
- WAVEWRITER ALPHA$10,400
- Proclaim DRG IPG$7,841
- Proclaim Family of SCS IPGs$4,427
- IonicRF Generator$1,845
- Proclaim IPG$1,730
- ReActiv8$631
- Prolate$591
- Axium INS DRG IPG$512
- BIOTRONIK$438
- GENERAL PAIN MANAGEMENT$421
- WaveWriter Alpha Prime 16$380
- Evoke$312
- Stimrouter for pain$296
- Nalu Neurostimulation System$293
How this compares
$194,294 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 25 | $13,858 |
| Xtampza ErOxycodone Myristate | 13 | $11,705 |
| Gabapentin | 256 | $4,374 |
| Fentanyl | 29 | $3,013 |
| Oxycodone Hcl | 112 | $2,495 |
| Lidocaine | 25 | $2,236 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 69 | $1,958 |
| Baclofen | 27 | $1,942 |
| Duloxetine Hcl | 82 | $1,824 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 94 | $1,365 |
| Celecoxib | 45 | $1,263 |
| Morphine Sulfate ErMorphine Sulfate | 39 | $1,027 |
| Pregabalin | 40 | $831 |
| Cephalexin | 26 | $642 |
| Trazodone Hcl | 51 | $635 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $196 | $13,85825 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $187 | $11,70513 claims |
| Upsher-smith Laboratories LLCTopiramate | $248 | $9214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.
Other pain medicine in Newport Beach
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.